RAPT Therapeutics, Inc. (RAPT)
NASDAQ: RAPT · Real-Time Price · USD
0.8500
-0.0393 (-4.42%)
At close: Apr 10, 2025, 4:00 PM
0.8365
-0.0135 (-1.59%)
After-hours: Apr 10, 2025, 7:51 PM EDT
RAPT Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
68
Market Cap
112.21M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RAPT News
- 4 weeks ago - RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 3 months ago - RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - GlobeNewsWire
- 3 months ago - RAPT Therapeutics Announces $150 Million Private Placement - GlobeNewsWire
- 5 months ago - Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury - Benzinga
- 9 months ago - RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus - Seeking Alpha
- 11 months ago - Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB) - Benzinga